Investment Thesis
Aligos Therapeutics exhibits development-stage biotech characteristics with minimal revenue ($2.8M), severe operating losses (-$26.9M), and annual cash burn of $23.3M, yielding approximately 15 months of financial runway at current rates. While YoY improvements in net income (+81.6%) and EPS (+88.3%) suggest operational progress, the company requires significant clinical/regulatory milestones or capital raises to survive.
Strengths
- YoY improvement in net loss indicates operational progress and cost management
- No debt burden with clean capital structure and zero leverage
- Current ratio of 2.56x demonstrates adequate short-term liquidity
Risks
- Limited financial runway of approximately 15 months at current burn rate
- Minimal revenue base of $2.8M against $26.9M operating losses
- Extreme negative margins (-951.6% operating, -814.1% net) indicate fundamental unprofitability
- Heavy reliance on capital markets or major clinical milestone achievement for survival
Key Metrics to Watch
- Quarterly cash burn rate and cash position trends
- Revenue growth and clinical development milestone announcements
- Operating loss trajectory and path to profitability timeline
Financial Metrics
Revenue
2.8M
Net Income
-23.0M
EPS (Diluted)
$-2.21
Free Cash Flow
-23.3M
Total Assets
64.6M
Cash
30.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-951.6%
Net Margin
-814.1%
ROE
-72.5%
ROA
-35.7%
FCF Margin
-821.8%
Balance Sheet & Liquidity
Current Ratio
2.56x
Quick Ratio
2.56x
Debt/Equity
0.00x
Debt/Assets
50.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T08:03:18.488764 |
Data as of: 2026-03-31 |
Powered by Claude AI